Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Sector: Medical
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
3m
6m
1y
2y
Ranking History
This Week
Last Week
Two Weeks Back
Three Weeks Back
Please login to view our current ranking data
Click here to login
No Information
No Information
No Information
Disclaimer
Headlines
Blog Articles
Premium News
Press Releases
SEC
AnaptysBio Names Director of Cell Biology; Joins from Regeneron, Adds Extensive Therapeutic Antibody Discovery Credentials
Nov 17, 2009 10:00 AM |
REGN
Regeneron Announces Conference Call to Discuss Expanded Antibody Collaboration with Sanofi-aventis
Nov 10, 2009 04:35 PM |
REGN
,
SNY
Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
Nov 10, 2009 04:30 PM |
REGN
,
SNY
Regeneron Reports Third Quarter 2009 Financial and Operating Results
Nov 03, 2009 07:01 AM |
REGN
BioMed Realty Trust Reports Third Quarter 2009 Operating and Financial Results
Oct 28, 2009 09:50 PM |
BMR
,
REGN
Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Oct 27, 2009 04:30 PM |
REGN
Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
Oct 27, 2009 09:30 AM |
REGN
Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
Oct 06, 2009 11:30 AM |
BMR
,
REGN
Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
Sep 14, 2009 07:01 AM |
AMD
,
BAY
,
REGN
Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued
Sep 11, 2009 04:05 PM |
REGN
,
SNY
More..
Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Inc., Whole Foods Market, Inc., Telecom Italia S.P.A., Mattel, Inc. And Photronics, Inc.
Jul 16, 2008 12:07 AM |
MAT
,
PLAB
,
REGN
,
WFMI
More..
Regeneron Announces Presentation at the 29th Annual Canaccord Adams Global Growth Conference
Aug 07, 2009 09:31 AM |
REGN
BioMed Realty Trust Commemorates Five-Year Anniversary As a Public Company ; Ringing NYSE Closing Bell(R) Today; Provides Tenant Update
Aug 06, 2009 06:53 AM |
ARNA
,
AVII
,
AZN
,
BMR
,
CEPH
,
EPCT
Regeneron Reports Second Quarter 2009 Financial and Operating Results
Aug 04, 2009 07:03 AM |
REGN
Regeneron Receives European Medicines Agency Positive Opinion for Marketing Authorization of Rilonacept for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Jul 24, 2009 07:19 AM |
REGN
First Patient Enrolled in Regeneron and Bayer HealthCare VEGF Trap-Eye Phase 3 Program in Central Retinal Vein Occlusion
Jul 23, 2009 07:06 AM |
REGN
Sanofi-aventis and Regeneron Announce Results from Phase 2 Study with Aflibercept (VEGF Trap) in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites
Jun 11, 2009 08:24 AM |
REGN
,
SAN
,
SNY
Regeneron Converts Interleukin-1 Antibody Opt-In Rights to Royalty Agreement
Jun 11, 2009 08:16 AM |
REGN
Regeneron Announces Presentation at the 8th Annual Needham Life Sciences Conference
Jun 08, 2009 09:46 AM |
REGN
Regeneron Announces Presentation at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
May 15, 2009 09:31 AM |
REGN
Regeneron Announces Presentation at the Deutsche Bank 34th Annual Healthcare Conference
May 13, 2009 09:33 AM |
REGN
More..
Form 4 REGENERON PHARMACEUTICAL For: Nov 13 Filed by: SING GEORGE L (10K)
Nov 16, 2009 02:20 PM
Form 4 REGENERON PHARMACEUTICAL For: Oct 29 Filed by: GOLDBERG MURRAY A (10K)
Nov 02, 2009 02:11 PM
Form 4 ROBERTS WILLIAM For: Sep 01 (10K)
Sep 03, 2009 03:38 PM
Form 4 ROBERTS WILLIAM For: Aug 12 (10K)
Aug 14, 2009 05:04 PM
Form 4 STAHL NEIL For: Jul 24 (10K)
Jul 27, 2009 06:17 PM
Form 4 REGENERON PHARMACEUTICAL For: Jun 23 Filed by: VAGELOS P ROY (10K)
Jun 26, 2009 03:09 PM
Form 4 ROBERTS WILLIAM For: Apr 27 (10K)
Apr 29, 2009 01:12 PM
Form 3 REGENERON PHARMACEUTICAL For: Apr 03 Filed by: Dworkin Peter (10K)
Apr 15, 2009 07:35 PM
Form 4 REGENERON PHARMACEUTICAL For: Feb 23 Filed by: BROWN MICHAEL S (10K)
Feb 24, 2009 01:32 PM
Form 4 REGENERON PHARMACEUTICAL For: Feb 20 Filed by: BAKER CHARLES A (10K)
Feb 24, 2009 09:43 AM
More..
Analyst Ratings
More Details
Sentiment Survey
Avg. Short Term
Avg. Long Term
Avg. Grade
More Details
Share Performance
Period
REGN
Compare to S&P
YTD
1.14 %
-16.45 %
4 Weeks
-1.33 %
-1.85 %
12 Weeks
-16.43 %
-21.57 %
More...
Financial Ratios
Earnings Performance
EPS Growth in Last Quarter:
94.74 %
EPS Growth in Last Year:
96.30 %
Sales Growth in Last Quarter:
30.46 %
Sales Growth in Last Quarter:
79.09 %
More...
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
